The Food and Drug Administration (FDA) recently asked for public input on CBD and cannabis. Specifically, they were seeking information in the realms of health and safety risks, marketing, labeling, sales, manufacturing, and product quality. The IRCCMH’s extensive background patient care in these specific areas inspired the Institute to provide comments and supporting research to the FDA public record. The ICCMH’s perspective is that rules that are holistic in their approach can accomplish the FDA’s goal to protect public health.
The IRCCMH leverages strong clinical expertise along with its network within the hemp industry. IRCCMH collaborates with universities, researchers, foundations, state institutions, and the highest caliber talent in the field. The IRCCMH has conducted small studies aimed at assisting policymakers to make the most informed decisions. The Institute has also advised states adopting or revising cannabis regulations. In addition to her research and education endeavors, Dr. Jan Roberts works with patients directly, resulting in firsthand knowledge of consumer safety concerns and accessibility issues for CBD products. Additionally, Dr. Jahan Marcu has helped create standards for the American Herbal Products Association’s Cannabis Committee, the American Herbal Pharmacopoeia Cannabis Monograph, and co-authored a CBD Labeling study published in JAMA.
The IRCCMH advised the FDA on the following core guidelines for CBD/cannabis products:
The IRCCMH is moving forward with a multitude of projects in regards to safety standards, regulations, and accredited training for CBD and cannabis products. We hope that the FDA strongly considers the public commentary provided, and works with frontrunners in the cannabis industry to create informed decisions that keep public health and product viability in mind.
The IRCCMH co-founders take on Alex Berenson's book "Tell Your Kids". In this condensed version of the video, Jan and Jahan discuss their concerns regarding Alex Berenson's book "Tell Your Kids"
(NEW YORK) November 16, 2018- IRCCMH and the Cannabis Chemistry Subdivision of the American Chemical Society, a group within the Division of Chemical Health & Safety released a joint statement warning consumers using CBD products about potentially damaging additives and materials that can negatively impact consumers. Both CANN and IRCCMH suggest that consumers use CBD products from legal, licensed, and government-regulated facilities. These products are more likely to follow GMP or equivalent compliance with industry and safety standards.
IRCCMH co-founder Jahan Marcu, PhD is featured in the November issue of Prevention magazine. Dr. Marcu addresses the myths around CBD in the latest article.
(New York, NY) October 31, 2018 – Today, two nationally recognized groups announced a partnership to study the impact of cannabis on professional athletes. The two organizations are the International Research Center on Cannabis and Mental Health (IRCCMH) and Athletes for CARE Inc.
IRCCMH is a grant funded research center based in New York, that focuses on providing education and research on cannabis and mental health. Athletes for CARE is a Colorado based organization founded by former professional athletes united as one voice to advocate for research, education, and compassion when addressing important health issues facing athletes and the public.
“We are happy for this area of research to move forward with Athletes for CARE and its partners. The results from these studies could help inform policies, and address gaps in our understanding of the pharmacokinetics and pharmacodynamics that could explain the mechanism between cannabis and its effect on the prescription drug epidemic,” said Dr. Jahan Marcu, Co-founder of IRCCMH, Director of Experimental Pharmacology and Behavioral Research.
IRCCMH will work with Athletes for CARE and its partners to conduct surveys of former and potentially current professional athletes, focusing on analyzing the role that cannabis plays in wellbeing of professional athletes. “So much research has been done of the pathological use of cannabis that we’ve neglected to study how the therapeutic use of cannabis can positively impact people’s lives. Through our alliance, we have an opportunity to provide important data based on professional athletes’ experiences,” said Jan Roberts, LCSW, Co-founder of IRCCMH and Director of Translational Research.
“This is an exciting opportunity for everyone involved in the project. And the results have the potential to impact policy, change lives, and provide education for mental health professionals,” said Lindy Snider, a Co-founder and Chair of the Board of Director for Athletes for CARE. “The athletes in our organization each have the right and desire to understand how the use of this plant for medicinal application and therapeutic use can improve their lives as well as the lives of every patient or athlete.”
The preliminary data will assess cannabis’ impact on mood, prescription drug use, cognitive functioning, pain relief, recovering from injuries, and relational impact. Both IRCCMH and Athletes for CARE will assist with the recruiting of former and current athletes.
“It is imperative we leverage scientific research to understand options to make sports healthier and safer for athletes of all ages,” said Anna Valent, executive director, Athletes for CARE. “We believe this is an important step and Athletes for CARE is honored to partner with IRCCMH on this project.”
About International Research Center on Cannabis and Mental Health (IRCCMH)
IRCCMH is a research, education, and consulting institute located in New York City that is focused on cannabis and its impact on mental health. IRCCMH is a grant-funded organization that partners with researchers worldwide on both translational and experimental pharmacological studies. IRCCMH serves as an educator and consultant to state governments, universities, clinicians, labs, and consumers. Its focus is to provide objective research on cannabis and its therapeutic use by bridging the gap between the lab and the patient.
About Athletes for CARE
Athletes for CARE (A4C) is a not-for-profit organization dedicated to creating a community where athletes can find support, opportunity, and purpose in life after a career in sports. A4C was founded by a group of pro athletes who are uniting as one voice to advocate for research, education, and compassion when addressing critical health issues facing athletes and the public at large.
(August 5, 2018) Jan Roberts, CEO and Director of Translational Research at IRCCMH, recently published "Medical Cannabis in Adult Mental Health Settings: Reconstructing One of the Most Maligned Medications in the United States" in the Clinical Social Work Journal. The Clinical Social Work Journal is one of the most reputable peer-reviewed journals in the clinical social work field.
This article aims to educate mental health clinicians on the history of medicinal cannabis use, the implications from US policy impacting research agendas and continued stigmatization. Borrowing from social work and sociological analysis, this article aims to highlight issues that clinicians need to be aware when supporting therapeutic cannabis use with patients.
(July 19, 2018)
Co-Founders Jan Roberts, LCSW and Dr. Jahan Marcu were interviewed by Merry Jane Magazine in an article exploring potency's influence of cannabis addiction.
(July 11, 2018)
SPECIAL ISSUE: Cannabis and Mental Health: Issues Impacting Clinical Social Work Practice
The Special Issue of Clinical Social Work Journal (CSWJ) will explore the role of medical cannabis and mental health in social work practice. With the increasing number of medical cannabis patients, the disjointed state programs that have been created as a response to federal prohibition, and current research on cannabis and mental health, it is essential for social work practitioners and educators to understand the benefits, risks, current research findings, and issues impacting clinical practice with clients using medical cannabis.
Jan L. Roberts, LCSW- Co-Founder, International Research Center on Cannabis and Mental Health (IRCCMH), CEO of Partners in Health and Wellbeing (NY and DE), and Doctoral Student and Adjunct Instructor, NYU Silver School of Social Work email: firstname.lastname@example.org or email@example.com
Amanda Reiman, PhD- Former Director of Research and Patient Services at Berkeley Patients Group and the Manager of Marijuana Law and Policy for the Drug Policy Alliance. Former lecturer at University of California-Berkley
Currently, Dr. Reiman is currently the Head of Community Relations for Flow Canna.
Authors should follow the guidelines for writing and submitting articles for which may be found at: http://www.springer.com/psychology/journal/10615
Manuscripts should be no more than 20-25 pages including references. All articles will be peer-reviewed. Submissions are due by November 10, 2018.
(July 1, 2018) Jan Roberts, CEO of IRCCMH, announced the funding of a Seed Grant by NYU expanding the pilot project for Ms. Roberts' study on mental health clinicians and knowledge/attitudes on cannabis. The expanded project will include members of IRCCMH working with Primary Investigator Lala Straussner, Ph.D., faculty at NYU and Editor of the Journal of Social Work Practice in the Addictions.
(April 16, 2018) IRCCMH launched a new survey targeting mental health clinicians and their knowledge and attitudes about cannabis and mental health issues. This international research endeavor is focused on determining educational gaps and associated beliefs around cannabis.
Aligned with the Silver School of Social Work at NYU, the first project involves research on mental health clinician attitudes and knowledge surrounding cannabis and mental health (NYU IRB-FY2018-1951). "We're really excited to see this study begin. It marks the first project for IRCCMH, but we have a few others in the pipeline" stated Jan Roberts, Co-Founder of the International Research Center on Cannabis and Mental Health.
Ms. Roberts stated that she and her collaborator, Dr. Jahan Marcu, had plans for two additional studies slated for Summer 2018. This project was approved by NYU's IRB with Lala Straussner, Ph.D. listed as PI.